Search Results - "Valantin, MA"

CP-142 Antiretroviral therapy optimisation in multitreated hiv patients: clinical and pharmacoeconomic approach in the ecovir study by Durand, L, Valantin, MA, Ktorza, N, Lenclume, L, Peytavin, G, Wirden, M, Costagliola, D, Assoumou, L, Katlama, C, Patrick, T

“…BackgroundSome patients infected with multiresistant HIV receive lifelong antiretroviral (ARV) treatments. Long term drug effects on the patient and economic…”
Get full text

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136 by KATLAMA, Christine, VALANTIN, Marc A, MARCELIN, Anne G, FLANDRE, Philippe, ALGARTE-GENIN, Michele, DUVIVIER, Claudine, LAMBERT-NICLOT, Sidonie, GIRARD, Pierre M, MOLINA, Jean M, HOEN, Bruno, PAKIANATHER, Sophie, PEYTAVIN, Gilles

“…Darunavir/ritonavir (darunavir/r) maintenance strategy, in patients with suppressed HIV RNA viremia, is a potential long-term strategy to avoid nucleoside…”
Get full text

Comparison of HIV-infected and non-infected patients undergoing bariatric surgery: the ObeVIH study by Pourcher, V., Capeau, J., Dudoit, Y., Boccara, F., Soulié, C., Ndoadoumgue, AL, Charlotte, F., Fellahi, S., Bastard, JP, Béréziat, V., Lagathu, C., Marcelin, AG, Peytavin, G., Boutron-Ruault, MC, Tubbax, C., D'Avout D’Auerstaedt, A., Valantin, MA, Schneider, L., Costagliola, D., Katlama, C., Assoumou, L., Pourcher, G.

Get full text

Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co‐infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End‐Stage Liver Disease as Compared to HCV Mono‐infected Patients by Salmon‐Ceron, Dominique, Nahon, Pierre, Layese, Richard, Bourcier, Valérie, Sogni, Philippe, Bani‐Sadr, Firouze, Audureau, Etienne, Merchadou, Laurence, Dabis, François, Wittkop, Linda, Roudot‐Thoraval, Françoise

“…It is widely accepted that human immunodeficiency virus (HIV) infection is a risk factor for increased severity of hepatitis C virus (HCV) liver disease…”
Get full text

Association between ABCC2 Gene Haplotypes and Tenofovir-Induced Proximal Tubulopathy by Izzedine, Hassane, Hulot, Jean-Sebastien, Villard, Eric, Goyenvalle, Catherine, Dominguez, Stephanie, Ghosn, Jade, Valantin, Marc Antoine, Lechat, Philippe, Deray, and Gilbert

“…BackgroundTenofovir disoproxil fumarate (TDF) may induce renal proximal tubulopathy (rPT). There are no data on pharmacogenomic predictors of rPT in the genes…”
Get full text

Tolerance and durability of abacavir/lamivudine (ABC/3TC)‐containing regimens: results from a large prospective French cohort by Cuzin, L, Allavena, C, Levy‐Bachelot, L, Valantin, MA, Mellliez, H, Pugliese, P, Poizot‐Martin, I, Duvivier, C, Finkielsztejn, L, Abel, S

“…7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK…”
Get full text

Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA by Valantin, Marc-Antoine, Aubron-Olivier, Camille, Ghosn, Jade, Laglenne, Elisabeth, Pauchard, Michelle, Schoen, Hélène, Bousquet, Raymond, Katz, Philippe, Costagliola, Dominique, Katlama, Christine

“…In the absence of currently available therapy to manage facial lipoatrophy, strategies used to compensate for facial fat loss warrant clinical evaluation. The…”
Get full text

Long-term efficacy of darunavir/ritonavir monotherapy in patients with HIV-1 viral suppression: week 96 results from the MONOI ANRS 136 study by Valantin, M. A., Lambert-Niclot, S., Flandre, P., Morand-Joubert, L., Cabiè, A., Meynard, J. L., Ponscarme, D., Ajana, F., Slama, L., Curjol, A., Cuzin, L., Schneider, L., Taburet, A. M., Marcelin, A. G., Katlama, C.

“…Objectives Long-term results at week 96 are needed to evaluate the capacity of the darunavir/ritonavir monotherapy strategy to maintain a sustained control of…”
Get full text

A large French prospective cohort of HIV‐infected patients: the Nadis Cohort by Pugliese, P, Cuzin, L, Cabié, A, Poizot‐Martin, I, Allavena, C, Duvivier, C, El Guedj, M, De La Tribonnière, X, Valantin, MA, Dellamonica, P

“…Objectives The aim of this article is to describe the development of a dynamic French cohort of HIV‐infected patients, the methodological issues and decisions…”
Get full text

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens by MARCELIN, A. G, CHARPENTIER, C, CALVEZ, V, WIRDEN, M, LANDMAN, R, VALANTIN, M. A, SIMON, A, KATLAMA, C, YENI, P, DESCAMPS, D, AUBRON-OLIVIER, C

“…To compare the frequency of the selection of the M184V/I resistance mutation in HIV-infected patients who experienced virological failure while receiving…”
Get full text

Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy by Semaille, C, Le Strat, Y, Chiron, E, Chemlal, K, Valantin, M A, Serre, P, Caté, L, Barbier, C, Jauffret-Roustide, M

“…We evaluated prevalence of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) among prison inmates in France in 2010, in a cross-sectional…”
Get full text

Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120) by Rozenberg, Sylvie, Lanoy, Emillie, Bentata, Michelle, Viard, Jean-Paul, Valantin, Marc Antoine, Missy, Pascale, Darasteanu, Iuliana, Roux, Christian, Kolta, Sami, Costagliola, Dominique

“…Low bone mineral density (BMD) is common in HIV-infected patients. Bisphosphonates such as alendronate potently inhibit bone resorption and are effective…”
Get more information

HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients by Salmon, D, Bani-Sadr, F, Gilbert, C, Rosenthal, E, Valantin, M.A, Simon, A, Neau, D, Morlat, P, Loko, M.A, Wittkop, L, Dabis, F

“…Highlights • SVR12 was 63% in a real-life setting in HIV/HCV patients treated with TVR or BOC. • Low HCV VL and virological response at W4 were the 2 factors…”
Get full text

Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence? by IZZEDINE, Hassane, THIBAULT, Vincent, VALANTIN, Marc Antoine, PEVTAVIN, Gilles, SCHNEIDER, Luminita, BENHAMOU, Yves

“…Tenofovir disoproxil fumarate (TDF) is the first nucleotide reverse transcriptase inhibitor used in the management of HIV, hepatitis B and HIV/hepatitis B…”
Get full text

Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS 3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis ( ANRS HC 31 SOFTRIH study) by Rosenthal, E, Fougerou‐Leurent, C, Renault, A, Carrieri, MP, Marcellin, F, Garraffo, R, Teicher, E, Aumaitre, H, Lacombe, K, Bailly, F, Billaud, E, Chevaliez, S, Dominguez, S, Valantin, MA, Reynes, J, Naqvi, A, Cotte, L, Metivier, S, Leroy, V, Dupon, M, Allegre, T, De Truchis, P, Jeantils, V, Chas, J, Salmon‐Ceron, D, Morlat, P, Neau, D, Perré, P, Piroth, L, Pol, S, Bourlière, M, Pageaux, GP, Alric, L, Zucman, D, Girard, PM, Poizot‐Martin, I, Yazdanpanah, Y, Raffi, F, Pabic, E Le, Tual, C, Pailhé, A, Amri, I, Bellissant, E, Molina, JM

“…Objectives Studies evaluating the efficacy and safety of the fixed‐dose combination ledipasvir ( LDV )/sofosbuvir ( SOF ) in patients coinfected with HIV ‐1…”
Get full text

Effects of rosuvastatin versus pravastatin on low-density lipoprotein diameter in HIV-1-infected patients receiving ritonavir-boosted protease inhibitor by BITTAR, Randa, GIRAL, Philippe, ASLANGUL, Elisabeth, ASSOUMOU, Lambert, VALANTIN, Marc A, KALMYKOVA, Olga, FEDERSPIEL, Marie C, CHERFILS, Corinne, COSTAGLIOLA, Dominique, BONNEFONT-ROUSSELOT, Dominique

“…HIV infection is associated with an atherogenic lipoprotein profile, and ritonavir-boosted protease inhibitors exacerbate this phenotype. We evaluated the…”
Get full text

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients by Valantin, M. A., Bittar, R., de Truchis, P., Bollens, D., Slama, L., Giral, P., Bonnefont-Rousselot, D., Pétour, P., Aubron-Olivier, C., Costagliola, D., Katlama, C.

“…Objectives To assess the impact of switching to tenofovir disoproxil fumarate + emtricitabine on lipid parameters. Methods HIV-infected patients with plasma…”
Get full text

Body fat distribution in HIV‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS136 Substudy by Valantin, MA, Kolta, S, Flandre, P, Algarte Genin, M, Meynard, JL, Ponscarme, D, Slama, L, Cuzin, L, Kerviler, E, Inaoui, R, Katlama, C

“…Objectives The aim of the study was to evaluate fat tissue distribution in HIV‐infected patients with suppressed viraemia treated with darunavir/ritonavir…”
Get full text

Acute hepatitis C in HIV‐infected men who have sex with men by Ghosn, J, Pierre‐François, S, Thibault, V, Duvivier, C, Tubiana, R, Simon, A, Valantin, MA, Dominguez, S, Caumes, E, Katlama, C

“…Background Hepatitis C virus (HCV) is usually transmitted via the parenteral route, but there are widely discrepant findings on its possible sexual…”
Get full text

Body fat distribution in HIV ‐infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI‐ANRS 136 Substudy by Valantin, MA, Kolta, S, Flandre, P, Algarte Genin, M, Meynard, JL, Ponscarme, D, Slama, L, Cuzin, L, de Kerviler, E, Inaoui, R, Katlama, C

“…Objectives The aim of the study was to evaluate fat tissue distribution in HIV ‐infected patients with suppressed viraemia treated with darunavir/ritonavir…”
Get full text